{
    "organizations": [],
    "uuid": "502c6dddaee4057e8522b2bbbed9e1cab65eee1a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-erytech-pharma-selects-triple-nega/brief-erytech-pharma-selects-triple-negative-breast-cancer-as-next-indication-for-eryaspase-idUSFWN1Q301L",
    "ord_in_thread": 0,
    "title": "Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - ERYTECH PHARMA SA:\n* ‍ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE​\n* ‍SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-13T14:42:00.000+02:00",
    "crawled": "2018-02-14T12:24:11.034+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "erytech",
        "pharma",
        "sa",
        "selects",
        "triple",
        "negative",
        "breast",
        "cancer",
        "next",
        "indication",
        "activity",
        "phase",
        "clinical",
        "study",
        "ongoing",
        "patient",
        "enrollment",
        "expected",
        "start",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}